Sinopharm Positions Itself For MNCs That May Need To Change Sales Models In China
This article was originally published in PharmAsia News
Executive Summary
China’s largest pharmaceutical distributor has built up a web of subsidiaries to expand its manufacturing and distribution capabilities. The company said global pharma companies may need to change their sales models in China as a result of corruption probes and it wants to be first in line to help.
You may also be interested in...
China Distributor Consolidation Heats Up: Sinopharm Looks To Raise $440 Million Ahead Of Shanghai Pharma IPO
SHANGHAI - China's largest drug distributor Sinopharm Group Co. Ltd. April 25 placed a secondary offering of roughly 138 million H shares in Hong Kong looking to raise HK$3.4 billion ($440 million) to fund more acquisitions. The move comes just ahead of the initial public offering in Hong Kong of Sinopharm's biggest competitor Shanghai Pharmaceutical Holdings Co. Ltd, and will add more heat to the consolidation war in China's distribution sector
Southeast Asian Regulators Ramp Up Anti-Corruption, Bribery Enforcement Ahead of ASEAN Pact
Regulators in Southeast Asia are working to tighten bribery and corruption enforcement as part of a broader push ahead of an Association of Southeast Asian Nations trade pact in 2015 for greater transparency in pharmaceuticals.
St. Jude Introduces Allure Quadra To Hong Kong As It Seeks APAC Rebound For Pacemakers
The first commercial implant for St. Jude’s Allure Quadra in Hong Kong is a sign for optimism for its pacemaker business after last year’s disappointments in Japan.